Tumor markers monitor disease, not screen for it. Oncogene and suppressor pairs are a common recall list.
Markers
- Alpha-fetoprotein: hepatocellular carcinoma and yolk sac tumor.
- CA-125: ovarian cancer.
- CA 19-9: pancreatic cancer.
- CEA: colorectal cancer.
- PSA: prostate cancer.
- Beta-hCG: choriocarcinoma, hydatidiform mole and germ cell tumors.
- Calcitonin: medullary thyroid carcinoma.
- S-100: melanoma and neural tumors.
Genes
RAS (colorectal, pancreatic), HER2/neu (breast, trastuzumab), MYC (Burkitt), BCR-ABL (CML), RET (MEN2), ALK (lung). Tumor suppressors: p53 (Li-Fraumeni), RB (retinoblastoma, E2F control), APC (FAP), BRCA1 and BRCA2, NF1 and NF2, VHL.
Principle
Oncogenes need one activating hit; suppressors need two (Knudson hypothesis).
Keep going in hematology and oncology
- Breast cancer: types, receptors, BRCA and screening
- Chemotherapy drugs: mechanisms and toxicities
- Paraneoplastic syndromes and oncologic emergencies
- Porphyrias, lead poisoning and heme synthesis